Toxicity comparison of neoadjuvant versus adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in radical cystectomy patients

Treatment options for muscle-invasive ur

Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin : Report of Southwest Oncology Group Trial 8733

✍ Celestia S. Higano; Catherine M. Tangen; Wael A. Sakr; James Faulkner; Saul E. R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB

## Abstract ## BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates for cisplatin‐based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients. ## METHODS. Eligible patients had pr